Abstract: Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.

Abstract: A method includes receiving, from a mobile device, a request in a telecommunications system to invoke operations from an automation platform executed by processing circuitry to perform one or more of: executing, by the processing circuitry, one or more existing simulated failure experiments for the telecommunications system; determining, by the processing circuitry, whether a simulated failure blueprint is configured for specific simulated failure cases exist on the automation platform; determining, by the processing circuitry, whether a simulated failure template is configured to accept a targeted telecommunications domain and failure parameters exist on the automation platform; or instructing the mobile device to display recommended simulated failure experiments with selectable telecommunications domains and selectable failure parameters.

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.

Abstract: A compound of Formula (I) is provided: where the variables are defined herein.

Abstract: The approach to the current problem of plastic deformation on the walls of the transportation truck is the development of a tribodynamic cell. This geometrically manufactured shape is able to reduce the force of more than 60.00% in a truck, more than 80.00% as a unit cell at standard speeds, and 90.00% at sonic range velocities. This reduction signifies an economic savings in fuel, service life of the transportation system, as well as reducing the carbon footprint locally and worldwide. Strategically, the tribodynamic cell embodiments convert the immediate surrounding airflow into a surface capable of lowering friction drastically and achieving supersonic speeds in half the time compared to a surface without the geometrically enhanced approach.

Abstract: The present embodiments provide compounds of Formula I, pharmaceutical compositions of the compounds, and methods for treating diseases such as cancer.

Abstract: A hydraulic pump includes a casing, and an impeller pump having a rotor that is rotationally mobile with respect to the casing about a first axis. The rotor includes several blades in helix form, a transition zone belonging to the casing and having, on the side of the impeller pump, a ramp in helix form developing in the same direction as the helix form of the blades. A trochoid pump includes a rotor with outer toothing secured to the rotor of the impeller pump. A rotor with internal toothing is rotationally mobile with respect to the casing about a second axis parallel to and offset from the first axis. The trochoid pump is fed by the impeller pump through the transition zone running along the ramp.

Abstract: The approach to the current problem of plastic deformation on the walls of the transportation truck is the development of a tribodynamic cell. This geometrically manufactured shape is able to reduce the force of more than 60.00% in a truck, more than 80.00% as a unit cell at standard speeds, and 90.00% at sonic range velocities. This reduction signifies an economic savings in fuel, service life of the transportation system, as well as reducing the carbon footprint locally and worldwide. Strategically, the tribodynamic cell embodiments convert the immediate surrounding airflow into a surface capable of lowering friction drastically and achieving supersonic speeds in half the time compared to a surface without the geometrically enhanced approach.

Abstract: Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

Abstract: A connector pin includes a stem extending between a head and an opposite foot. The stem includes a neck having a plurality of sections which may be planar forming edges. A retention member including a collar and arms extending therefrom is retained around said pin, the inner surface of the collar correspondingly configured to the sections and edges of the neck for a frictional fit. The pin is insertable and retained within a receiver in overlapping mats. Pockets in the receiver hold the retention member arms and prevent rotational motion of the retention member. The pin is selectively movable relative to the retention member by rotational motion by application of force to the pin sufficient to overcome the threshold level of friction holding the sections of the neck at the collar. Locking the pin is achieved when extension members of the pin foot are misaligned with the retention member arms.

Abstract: A compound of Formula (I) is provided: (I) where the variables are defined herein.

Abstract: Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

Abstract: A hydraulic pump includes a casing, an impellor pump comprising a rotor that is rotationally mobile with respect to the casing about a first axis, the rotor comprising several blades in helix form, a transition zone belonging to the casing and having, on the side of the impellor pump, a ramp in helix form developing in the same direction as the helix form of the blades, a trochoid pump comprising a rotor with outer toothing secured to the rotor of the impellor pump, and a rotor with internal toothing that is rotationally mobile with respect to the casing about a second axis parallel to and offset from the first axis, the trochoid pump being fed by the impellor pump through the transition zone running along the ramp.

Abstract: Compounds with KRAS G12C inhibitory active are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation.

Abstract: Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2e and R2d have the meanings provided in the specification.

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formula: wherein the letters and symbols a, b, c, d, e, f, A, R1, X1, Ar1 and Ar2 have the meanings provided in the specification.

Abstract: A method includes receiving, from a mobile device, a request in a telecommunications system to invoke operations from an automation platform executed by processing circuitry to perform one or more of: executing, by the processing circuitry, one or more existing simulated failure experiments for the telecommunications system; determining, by the processing circuitry, whether a simulated failure blueprint is configured for specific simulated failure cases exist on the automation platform; determining, by the processing circuitry, whether a simulated failure template is configured to accept a targeted telecommunications domain and failure parameters exist on the automation platform; or instructing the mobile device to display recommended simulated failure experiments with selectable telecommunications domains and selectable failure parameters.

Abstract: Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae: wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.